Placebo

Possible Dangers and SPF Misconceptions of Sunscreens for Sunbathing Investigated by Scientist, Dr. Win L. Chiou

Retrieved on: 
Thursday, March 2, 2023
SPFS, Multimedia, Acne, FDA, Placebo, Ageing, University, Skin, Journal, Sunburn, Blood, Sun, SPF, University of Illinois Chicago, Tanning, Organization, Publication, Indian Journal of Pharmaceutical Sciences, Canker, Criticism of the Food and Drug Administration, Sunlight, Dermatology, UVA, Pharmacy, Food, Skin cancer, Cosmetics, Pharmaceutical industry, Chiou Ho-shun

Yet, skin cancers continue to rise, so are sunscreens effective and safe as thought to be?

Key Points: 
  • Yet, skin cancers continue to rise, so are sunscreens effective and safe as thought to be?
  • Use of SPF sunscreen often results in inconsistent and missed areas on exposed skin, resulting in sunburn (1).
  • We may need to reexamine the notion that the higher the SPF, the better the sunscreen.
  • Win Chiou, President of Chiou Consulting Inc, can be reached at 630-789-9081 or at [email protected] .

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, March 2, 2023
Maker, NYSE, IBM, Survival, MRI, Biologics license application, ESS, Register, P.C, CFR, Letter, Prospectus, CSF, ORR, Safety, Overalls, Element, IPO, CNS, Risk, Form 10-Q, Marketing, Therapy, Radiation, BLA, Bank statement, Neuroblastoma, Advisory Committee, ESI, OS, Brain, Memorial Sloan Kettering Cancer Center, Registration statement, Shareholder, Class, Knowledge, News, Sale, RTF, Rule, LM, Person, FDA, Observation, Central nervous system, Disclosure, Form 10-K, Patient, Database, Spinal cord, Placebo, Partnership, NB, Vaccine, Medical imaging, Pharmaceutical industry, Nursing, Medical device, Cryptocurrency, Audit, Security (finance), Tobacco, Plaintiff, Form, Defendant

According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.

Key Points: 
  • According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.
  • The efficacy population in Study 03-133 consisted of a subset of 94 patients ages 0.9 to 13 years.
  • As of the time this Complaint was filed, Bioventus's Class A common stock continues to trade below the $13.00 per share Offering price, damaging investors.
  • The market price of IBM securities declined sharply upon public disclosure of the facts alleged herein to the injury of Plaintiff and Class members.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, February 25, 2023
Maker, Overalls, Memorial Sloan Kettering Cancer Center, Prospectus, Observation, Registration statement, Neuroblastoma, IPO, Safety, Therapy, Central nervous system, Advisory Committee, ESS, LM, RTF, Patient, Database, MRI, NB, Biologics license application, IBM, Class, Sale, Knowledge, Spinal cord, Register, NYSE, Partnership, CSF, Brain, OS, CNS, Letter, ORR, Bank statement, Placebo, Form 10-K, Rule, ESI, Person, Marketing, News, Shareholder, Survival, CFR, BLA, Risk, FDA, Element, P.C, Radiation, Form 10-Q, Disclosure, Vaccine, Medical imaging, Pharmaceutical industry, Nursing, Medical device, Cryptocurrency, Audit, Security (finance), Tobacco, Defendant, Plaintiff, Form

According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.

Key Points: 
  • According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.
  • The efficacy population in Study 03-133 consisted of a subset of 94 patients ages 0.9 to 13 years.
  • As of the time this Complaint was filed, Bioventus's Class A common stock continues to trade below the $13.00 per share Offering price, damaging investors.
  • The market price of IBM securities declined sharply upon public disclosure of the facts alleged herein to the injury of Plaintiff and Class members.

Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress

Retrieved on: 
Wednesday, February 22, 2023
Maintenance, NORA, Congress, Development, ESMO, Shanghai Cancer Center, III, Placebo, MD, PDS, European Society for Medical Oncology, ADP, Ovarian cancer, Peking Union Medical College, Survival, Data analysis, OS, MOS, Peking Union Medical College Hospital, Mutation, Progression-free survival, ISD, IDS, Fudan University, Medicine, Borat Subsequent Moviefilm, PFS, Oncology, Pharmaceutical industry, Patient, Niraparib

One presentation will feature an ad hoc interim OS data analysis of the Phase 3 NORA trial, showing how niraparib maintenance therapy with an individualized starting dose (ISD) provided a favorable OS (OS; secondary endpoint) trend versus placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of biomarker status.

Key Points: 
  • One presentation will feature an ad hoc interim OS data analysis of the Phase 3 NORA trial, showing how niraparib maintenance therapy with an individualized starting dose (ISD) provided a favorable OS (OS; secondary endpoint) trend versus placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of biomarker status.
  • The median overall survival (mOS) in the niraparib-treated group was numerically higher (46.3 months) compared to 43.4 months in placebo [HR=0.82; 95% CI, 0.56-1.21].
  • This new data analysis explores the treatment effect of niraparib versus placebo on OS adjusted for subsequent poly (ADP-ribose) polymerase inhibitor (PARPi) use in the placebo group.
  • Another presentation will feature a post hoc analysis from the randomized, double-blind, placebo-controlled Phase 3 PRIME trial, with results showing niraparib associated with improved progression-free survival (PFS) regardless of surgical timing and residual disease status compared with placebo in patients with newly diagnosed advanced ovarian cancer in China.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, February 14, 2023
Maker, Bank statement, Prospectus, Rule, CFR, Safety, NYSE, LM, Placebo, CSF, Person, Partnership, Memorial Sloan Kettering Cancer Center, NB, Brain, Element, Form 10-Q, Radiation, News, Form 10-K, CNS, Risk, IPO, ORR, Knowledge, Survival, RTF, Marketing, Neuroblastoma, FDA, Observation, ESI, Spinal cord, IBM, Advisory Committee, OS, MRI, Patient, Disclosure, Database, Sale, Letter, Therapy, Central nervous system, BLA, Registration statement, Register, Biologics license application, P.C, ESS, Class, Overalls, Shareholder, Vaccine, Medical imaging, Pharmaceutical industry, Nursing, Medical device, Cryptocurrency, Audit, Security (finance), Tobacco, Defendant, Plaintiff, Form

According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.

Key Points: 
  • According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.
  • The efficacy population in Study 03-133 consisted of a subset of 94 patients ages 0.9 to 13 years.
  • As of the time this Complaint was filed, Bioventus's Class A common stock continues to trade below the $13.00 per share Offering price, damaging investors.
  • The market price of IBM securities declined sharply upon public disclosure of the facts alleged herein to the injury of Plaintiff and Class members.

ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients

Retrieved on: 
Tuesday, January 31, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, NAFLD, NR, Brain, Syndrome, Radical, KTH, Trial of the century, PD, CMA, Neuron, Hyperaemia, Regulatory affairs, Royal institute, Royal Society Te Apārangi, Translational Neurodegeneration, Patient, NAC, Clinical trial, Liver, Cell, Ageing, Molecular Systems Biology, Oxidative stress, Research, Science for Life Laboratory, Neurodegenerative disease, Science, Risk, ChromaDex, Death, Mitochondrion, ScienceDirect, Systems biology, AD, Serine, COVID-19, Advanced Science, Fatty liver disease, Necrosis, Reactive oxygen species, Dietary supplement, Medical device, Placebo

This study marks a milestone as it is the first-ever peer-reviewed clinical study to investigate the effects of CMA supplementation in human AD patients.

Key Points: 
  • This study marks a milestone as it is the first-ever peer-reviewed clinical study to investigate the effects of CMA supplementation in human AD patients.
  • In a preclinical study, AD and Parkinson’s disease (PD) rat models were used to demonstrate CMA supplementation resulted in improved brain and liver metabolism.
  • “The promising results showcased that activation of mitochondria with the administration of CMA led to improved cognitive functions in AD patients,” Dr. Mardinoglu remarked.
  • “Further research to determine if CMA improves metabolic abnormalities and cognitive functions in AD patients is warranted and we look forward to initiating a Phase 3 study in the near future.”

Y-MABS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Y-mAbs Therapeutics, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, January 20, 2023
Class Action Lawsuit, Professional Services, Legal, RTF, Database, Spinal cord, Radiation, Overalls, Memorial Sloan Kettering Cancer Center, Brain, OS, Element, CSF, Person, Therapy, Advisory Committee, Aerospace, Form 10-K, CNS, District court, Safety, FDA, LM, Biologics license application, Placebo, Telephone, Jeanne Eagels, Neuroblastoma, Marketing, Central nervous system, Survival, BLA, Patient, Observation, Court, ORR, NB, MRI, Letter, Disclosure, P.C, CFR, Medical imaging, Pharmaceutical industry, Petroleum jelly, Medicine, Medical device, Dietary supplement

Investors have until March 20, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until March 20, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.
  • Of those, approximately 50-60% are high-risk, and of those at high-risk who relapse, Y-mAbs believes approximately 20% will suffer from leptomeningeal (central nervous system) metastases from neuroblastoma.
  • The efficacy population in Study 03-133 consisted of a subset of 94 patients ages 0.9 to 13 years.

Chacruna Institute Launches New Spring Course - Now Open for Limited Enrollment

Retrieved on: 
Wednesday, January 4, 2023
Knowledge, Council, Social, MD, Research, Student, Canada Research Chair, University of Saskatchewan academics, Humanities, Health, SAN, CE, Medicine, Curriculum, University, Master of Science, North–South divide in the World, Placebo, Doctor of Philosophy, Indigenous, Psychotria viridis

SAN FRANCISCO, Jan. 4, 2023 /PRNewswire-PRWeb/ -- Through 16 live, virtual weekly meetings over the length of a spring semester, students will gain crucial insights as they explore issues absent from most other programs in the space of inquiry around how, where, and why particular knowledge about psychedelics is produced. By the culmination of the course, they will have a holistic understanding of which methods and inquiries are privileged in psychedelic science, which are marginalized, and which are unrepresented altogether. Classes will focus on questions like: How are certain variables selected in trials? How much value, if any, is assigned to particular forms of subjective experience when we study the therapeutic effects of psychedelics? How does knowledge production differ between the Global North and Global South? How are Indigenous perspectives incorporated into psychedelic research? Students can expect engaging discussions of key questions emerging in the current psychedelic landscape from the humanities to the sciences, presented by a diverse range of expert researchers and practitioners with firsthand knowledge in the field.

Key Points: 
  • The Chacruna Institute for Psychedelic Plant Medicine's newest course offering, Critical Perspectives on Knowledge Production in Psychedelic Science, begins January 24.
  • This course continues that remarkable tradition by featuring instructors with a wide variety of perspectives who are driving conversations in the field.
  • She notes that the course "is signature Chacruna – informed, provocative, and pushing this field in new directions by paying attention to voices who complicate it."
  • With this course, Chacruna continues its legacy as a leader in psychedelic science.

Signifier Medical Technologies Announces Conference Participation at CHEST 2022, Medtrade East and Maryland Sleep Society Annual Scientific Conference

Retrieved on: 
Tuesday, October 11, 2022
Health, FDA, Medical Devices, Health Technology, General Health, Research, Science, Tongue, Stroke, Somnolence, Patient, Sleep, OSA, Human, Research, Company, Health technology, Population health, Ageing, NMES, Placebo, Death, FDA, Signified and signifier, Solution, Pharmaceutical industry

Signifier Medical Technologies LLC (Signifier or the Company), a Boston-based medical technology company, announced participation in three upcoming medical conferences.

Key Points: 
  • Signifier Medical Technologies LLC (Signifier or the Company), a Boston-based medical technology company, announced participation in three upcoming medical conferences.
  • At each conference, Signifier will showcase its lead product eXciteOSA , the only FDA-authorized, non-invasive daytime therapy for primary snoring and mild obstructive sleep apnea.
  • In the companys booth at each conference, Signifier will have copies available of its recently released white paper, A descriptive analysis of objectively-monitored real-world adherence to eXciteOSA .
  • Details for the three conferences include:
    The Sheraton Baltimore North Hotel, Townson, Maryland
    Signifier is a pioneer in addressing the root causes of sleep disordered breathing.

Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder

Retrieved on: 
Thursday, October 6, 2022
National Institute, Drug overdose, Half-life, Therapy, Alcoholism, JAMA Psychiatry, Media, NASDAQ, Patient, Research, Risk, Endorphins, Drinking, National Institute on Alcohol Abuse and Alcoholism, Absorption, Centers for Disease Control and Prevention, WHO, Treatment, Trial of the century, Addiction, Naltrexone, PMID, Safety, Placebo, World Health Organization, GLOBE, Plasma, Ageing, NCHS, Death, Terminology, AUD, The Journal of Clinical Pharmacology, Epidemiology, Rural area, Pharmaceutical industry

Opiant launched its Phase 2 clinical study of OPNT002 for the treatment of alcohol use disorder in January 2022.

Key Points: 
  • Opiant launched its Phase 2 clinical study of OPNT002 for the treatment of alcohol use disorder in January 2022.
  • Clinical and preclinical studies have shown that alcohol releases endorphins, which are the brains endogenous opioids.
  • Alcohol use disorder is a chronic relapsing brain disease characterized by compulsive use of alcohol and the inability to control intake.
  • Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.